Mylan’s Fulphila has secured an 8% share

Mylan has declared itself “very happy” with the progress of its Fulphila (pegfilgrastim-jmdb) rival to Neulasta, after revealing that the biosimilar – co-developed with India’s Biocon – has captured just over 8% of the pegfilgrastim pre-filled syringe market in the US.